Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease
Identifieur interne : 000103 ( PascalFrancis/Checkpoint ); précédent : 000102; suivant : 000104Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease
Auteurs : Andrew Lees (neurologue) [Royaume-Uni] ; Stanley Fahn [États-Unis] ; Karla M. Eggert [Allemagne] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; Federico Micheli [Argentine] ; M. Maral Mouradian [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Eduardo Tolosa [Espagne] ; David Squillacote [États-Unis] ; Dinesh Kumar [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Background: Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. Methods: In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302. Results: For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day. Conclusions: Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.
Affiliations:
- Allemagne, Argentine, Autriche, Canada, Espagne, France, Royaume-Uni, États-Unis
- Angleterre, Catalogne, District de Giessen, Grand Londres, Hesse (Land), Midi-Pyrénées, New Jersey, Ontario, Texas, Tyrol (Land), État de New York
- Barcelone, Houston, Innsbruck, Londres, Marbourg, Toronto, Toulouse
- Baylor College of Medicine, National Hospital for Neurology and Neurosurgery, Université Toulouse III - Paul Sabatier, Université de Toronto, Université de Toulouse, Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:12-0113807Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease</title><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Reta Lila Weston Institute for Neurological Studies, University College London</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, Columbia University College of Physicians and Surgeons, New York</s1><s2>New York</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Toronto Western Hospital, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires</s1><s2>Buenos Aires</s2><s3>ARG</s3><sZ>6 aut.</sZ></inist:fA14><country>Argentine</country><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School</s1><s2>Piscataway, New Jersey</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine, New York</s1><s2>New York</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>10 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>12 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name><affiliation wicri:level="2"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1><s2>Woodcliff Lake, New Jersey</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name><affiliation wicri:level="2"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1><s2>Woodcliff Lake, New Jersey</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0113807</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0113807 INIST</idno><idno type="RBID">Pascal:12-0113807</idno><idno type="wicri:Area/PascalFrancis/Corpus">000281</idno><idno type="wicri:Area/PascalFrancis/Curation">002A33</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000103</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease</title><author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Reta Lila Weston Institute for Neurological Studies, University College London</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName>National Hospital for Neurology and Neurosurgery</orgName></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Neurology, Columbia University College of Physicians and Surgeons, New York</s1><s2>New York</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>Toronto Western Hospital, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires</s1><s2>Buenos Aires</s2><s3>ARG</s3><sZ>6 aut.</sZ></inist:fA14><country>Argentine</country><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name><affiliation wicri:level="2"><inist:fA14 i1="07"><s1>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School</s1><s2>Piscataway, New Jersey</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine, New York</s1><s2>New York</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>10 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>12 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name><affiliation wicri:level="2"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1><s2>Woodcliff Lake, New Jersey</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name><affiliation wicri:level="2"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1><s2>Woodcliff Lake, New Jersey</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AMPA receptor</term><term>Fluctuations</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Perampanel</term><term>Safety</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Pérampanel</term><term>Récepteur AMPA</term><term>Fluctuation</term><term>Sécurité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. Methods: In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302. Results: For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day. Conclusions: Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>27</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease</s1></fA08><fA11 i1="01" i2="1"><s1>LEES (Andrew)</s1></fA11><fA11 i1="02" i2="1"><s1>FAHN (Stanley)</s1></fA11><fA11 i1="03" i2="1"><s1>EGGERT (Karla M.)</s1></fA11><fA11 i1="04" i2="1"><s1>JANKOVIC (Joseph)</s1></fA11><fA11 i1="05" i2="1"><s1>LANG (Anthony)</s1></fA11><fA11 i1="06" i2="1"><s1>MICHELI (Federico)</s1></fA11><fA11 i1="07" i2="1"><s1>MARAL MOURADIAN (M.)</s1></fA11><fA11 i1="08" i2="1"><s1>OERTEL (Wolfgang H.)</s1></fA11><fA11 i1="09" i2="1"><s1>OLANOW (C. Warren)</s1></fA11><fA11 i1="10" i2="1"><s1>POEWE (Werner)</s1></fA11><fA11 i1="11" i2="1"><s1>RASCOL (Olivier)</s1></fA11><fA11 i1="12" i2="1"><s1>TOLOSA (Eduardo)</s1></fA11><fA11 i1="13" i2="1"><s1>SQUILLACOTE (David)</s1></fA11><fA11 i1="14" i2="1"><s1>KUMAR (Dinesh)</s1></fA11><fA14 i1="01"><s1>Reta Lila Weston Institute for Neurological Studies, University College London</s1><s2>London</s2><s3>GBR</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Neurology, Columbia University College of Physicians and Surgeons, New York</s1><s2>New York</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>3 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="04"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Toronto Western Hospital, University of Toronto</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires</s1><s2>Buenos Aires</s2><s3>ARG</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School</s1><s2>Piscataway, New Jersey</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Mount Sinai School of Medicine, New York</s1><s2>New York</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Neurology, Innsbruck Medical University</s1><s2>Innsbruck</s2><s3>AUT</s3><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse</s1><s2>Toulouse</s2><s3>FRA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="11"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>12 aut.</sZ></fA14><fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1><s2>Woodcliff Lake, New Jersey</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>14 aut.</sZ></fA14><fA20><s1>284-288</s1></fA20><fA21><s1>2012</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000508698420180</s5></fA43><fA44><s0>0000</s0><s1>© 2012 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>14 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>12-0113807</s0></fA47><fA60><s1>P</s1><s3>CC</s3></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. Methods: In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302. Results: For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day. Conclusions: Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pérampanel</s0><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Perampanel</s0><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Perampanel</s0><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Récepteur AMPA</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>AMPA receptor</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Receptor AMPA</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Fluctuation</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Fluctuations</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Fluctuación</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Sécurité</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Safety</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Seguridad</s0><s5>12</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Récepteur glutamate</s0><s5>42</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Glutamate receptor</s0><s5>42</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Receptor glutámato</s0><s5>42</s5></fC07><fN21><s1>086</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Allemagne</li><li>Argentine</li><li>Autriche</li><li>Canada</li><li>Espagne</li><li>France</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Catalogne</li><li>District de Giessen</li><li>Grand Londres</li><li>Hesse (Land)</li><li>Midi-Pyrénées</li><li>New Jersey</li><li>Ontario</li><li>Texas</li><li>Tyrol (Land)</li><li>État de New York</li></region><settlement><li>Barcelone</li><li>Houston</li><li>Innsbruck</li><li>Londres</li><li>Marbourg</li><li>Toronto</li><li>Toulouse</li></settlement><orgName><li>Baylor College of Medicine</li><li>National Hospital for Neurology and Neurosurgery</li><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toronto</li><li>Université de Toulouse</li><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name></region></country><country name="États-Unis"><region name="État de New York"><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name></region><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name></region><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name></country><country name="Canada"><region name="Ontario"><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name></region></country><country name="Argentine"><noRegion><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name></noRegion></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country><country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000103 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000103 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:12-0113807
|texte= Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |